HV and AIDS Articles LIbrary of Slides and Posters Hepatitis B Articles Hepatitis C Articles HIV-HCV and HIV-HBV Coinfection Articles ICAAC/IDSA 2008 CME/CE Newsletter Update

HIV and AIDS Articles
Atherosclerosis, Coronary Plaques, and Heart Rhythm Changes in People with HIV Zinc Finger Nuclease that Disables CCR5 Gene May Offer Potential New HIV Treatment Approach Studies Look at Long-term Safety of Tenofovir (Viread/Truvada/Atripla), including Kidney Toxicity and Bone Loss Should Antiretroviral Therapy Be Guided By Therapeutic Drug Monitoring? Experimental HIV Entry Inhibitor PRO 140 Demonstrates Favorable Activity Phase 2 Trial Investigational NNRTI RDEA806 Exhibits Promising Activity and Has High Barrier to Resistance Race/ethnicity and Income Impact HIV Treatment Access and Outcomes Maraviroc (Selzentry) Is Associated with Faster and Larger CD4 Cell Gains: MERIT Trial HIV Positive People on HAART Have an Elevated Risk of Pulmonary Hypertension Experimental NRTI Elvucitabine Suppresses HIV as Well as Lamivudine at 48 Weeks Risk of Hospitalization Remains High for 3 Months after Starting HAART Lopinavir/ritonavir (Kaletra) Monotherapy Produces Sustained HIV Suppression: IMANI-2 and OK04 Studies Fosamprenavir (Lexiva) Is Equally Effective with a Lower 100 mg Ritonavir (Norvir) Boosting Dose Experimental HIV Maturation Inhibitor Bevirimat Demonstrates Good Antiviral Activity and Favorable Safety Profile Is HIV Becoming More Virulent? Abacavir/lamivudine (Epzicom) plus Boosted Atazanavir (Reyataz) Provides Potent Antiviral Activity at All Viral Load Levels in ARIES Trial; Meta-analysis Favors Tenofovir/emtricitabine (Truvada) Boosted Atazanavir (Reyataz) and Lopinavir/ritonavir (Kaletra) Are Both Highly Effective through 96 Weeks, but Atazanavir Has Better Side Effects Profile: CASTLE Study Darunavir (Prezista) Is Safe and Effective in HIV Positive Children and Adolescents at 48 Weeks: DELPHI Trial Continuous HAART Associated with Elevated Risk of Bone Loss in SMART Treatment Interruption Trial Starting HAART with a CD4 Count of 351-500 Reduces Risk of Death by 71% Raltegravir (Isentress) Is as Effective as Efavirenz (Sustiva) at 48 Weeks in Treatment-naive Patients: STARTMRK Trial MERIT Reanalysis with More Sensitive Trofile Test Shows Maraviroc (Selzentry) Works as well as Efavirenz (Sustiva) in Patients New to Therapy Long-term Safety of Investigational CCR5 Antagonist Vicriviroc in Treatment-experienced Patients Efficacy and Safety of Boosted Darunavir (Prezista) Are Superior to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial
Hepatitis C Articles
Many U.S. Veterans -- both HIV Negative and HIV Positive -- Do Not Receive Treatment for Chronic Hepatitis C Hepatitis C Virus Infection Is Associated with Elevated Cardiovascular Risk despite Lower Blood Lipid Levels Another Study Confirms Hepatitis B Virus Suppresses Hepatitis C Virus Replication in HBV-HCV Coinfected Individuals
Hepatitis B Articles
Hepatitis B Virus Reverse Transcriptase Drug Resistance Mutations Lead to Treatment Failure
HIV-HCV and HIV-HBV Coinfection Articles
HAART Improves Hepatitis B Vaccine Response Regardless of CD4 Count Many U.S. Veterans -- both HIV Negative and HIV Positive -- Do Not Receive Treatment for Chronic Hepatitis C HAART Is Associated with Reduced Liver Inflammation in HIV-HCV Coinfected Patients Progression of Liver Fibrosis in HIV-HBV Coinfected Patients Taking Antiretroviral Agents Active against Hepatitis B Virus Higher Ribavirin Dose with Pre-emptive EPO for Anemia Does Not Improve Treatment Response in HIV-HCV Coinfected Patients Twice-weekly Pegylated Interferon alfa-2a (Pegasys) plus Ribavirin Improves Response in HIV-HCV Coinfected African-Americans Rate of HCV Coinfection Has Declined Sharply among HIV Positive People in Spain Rate of Chronic Hepatitis B among HIV Positive U.S. Patients in High, but Stable since Mid-1990s Drug Interaction Observed between NRTI Tenofovir (Viread) and Experimental Hepatitis C Protease Inhibitor Telaprevir Efficacy of Tenofovir (Viread) plus Emtricitabine (Emtriva) in HIV-HBV Coinfected Patients

ICAAC Coverage / IDSA Coverage
ICAAC 2008 Coverage / IDSA 2008 Coverage Washington, DC


ICAAC Coverage / IDSA Coverage
ICAAC 2008 Coverage / IDSA 2008 Coverage Washington, DC